Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director | June 14, 2023 | June 15, 2023 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Spero Therapeutics, Inc.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,000 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 10,000 · Balance 85,000 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2036-06-23 | Direct | 20,000 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Grant · Acquired 20,000 · Balance 20,000 F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 25, 2026 23:12 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001193125-26-283226 · ownership.xml · derivative · entry 2 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-06-23 F2 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 23:12 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-283226 · ownership.xml · nonDerivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:28 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087015 · ownership.xml · nonDerivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 12, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:25 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066622 · ownership.xml · nonDerivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on May 29, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 21:28 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-052701 · ownership.xml · nonDerivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on October 5, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:48 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 39,875 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-23-037390 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,875 Underlying: Common Stock · 39,875 shares Expires 2033-06-13 F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:14 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 15,471 | $1.29 Strike: $1.74 | $19,957.59 |
DisclosureSEC source: 0000899243-23-000983 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,471 Underlying: Common Stock · 15,471 shares Expires 2033-01-03 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $20,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 21:39 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-031495 · doc4.xml · nonDerivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on September 15, 2023, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001209191-22-037482 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 15, 2023 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 22:07 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 2,214 | $9.03 Strike: $13.19 | $19,992.42 |
DisclosureSEC source: 0000899243-22-001376 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,214 Underlying: Common Stock · 2,214 shares Expires 2032-01-05 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $20,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 20:52 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0000899243-21-033463 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 21:20 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 21,000 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001209191-21-044491 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: The options vest and become exercisable in 36 equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:30 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 1,314 | $13.31 Strike: $17.93 | $17,489.34 |
DisclosureSEC source: 0000899243-21-000695 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,314 Underlying: Common Stock · 1,314 shares Expires 2031-01-04 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $17,500 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 21:31 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.52 | $0.00 |
DisclosureSEC source: 0000899243-20-029327 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-10-27 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on October 27, 2021 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 00:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 5,408 | $6.47 Strike: $9.87 | $34,989.76 |
DisclosureSEC source: 0000899243-20-000628 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,408 Underlying: Common Stock · 5,408 shares Expires 2030-01-02 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $35,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:45 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015663 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 00:00 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015325 · doc4.xml · derivative · entry 1 VINK PATRICK V.J.J. · CIK 0001557501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.